Which contraceptive method has been FDA-approved as a treatment for endometriosis?

The SQ 104 DMPA, which is a subcutaneous form of depot medroxyprogesterone acetate, has received FDA approval specifically for the treatment of endometriosis. This method works by providing a consistent release of progestin, which helps to inhibit the growth of endometrial tissue and can alleviate symptoms associated with endometriosis, such as pain and heavy menstrual bleeding.

The hormonal mechanism of action is beneficial for managing endometriosis because it reduces the levels of estrogen that can stimulate the growth of endometrial cells outside the uterus. The transition to a subcutaneous formulation allows for easier administration and may improve patient compliance.

While other methods like the levonorgestrel IUD, combined oral contraceptives, and transdermal patches are often utilized in the management of endometriosis, they are not specifically FDA-approved for this purpose. These methods can help manage symptoms of endometriosis but do not carry the same formal approval for treatment as SQ 104 DMPA does.